Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib open-label extension in warm autoimmune hemolytic anemia
NL-OMON55183Phase 3Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fostamatinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: Incidence, frequency, seriousness, and severity of adverse events, Change from baseline in blood pressure and 26 more. Started May 2021; status: active, not recruiting.
02
Drugs
fostamatinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NL-OMON55183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55183.